2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update)
RECOMMENDATION 1 For newly diagnosed PCa, staging with a computed tomography (CT) scan of the chest, abdomen, and pelvis and bone scan (technetium-99mmethylene diphosphonate [99mTc-MDP]) should be performed for men with any high-risk features: PSA >20 ng/mL, Gleason score >7, clinical stage T3 or greater (Level of evidence 3, Strong recommendation).
Authors
- Neil Fleshner (ORCID: https://orcid.org/0000-0001-7407-7463)
- Alan So (ORCID: https://orcid.org/0000-0001-6465-057X)
- Adam Kinnaird (ORCID: https://orcid.org/0000-0002-4115-4327)
- Rodney H. Breau (ORCID: https://orcid.org/0000-0003-2344-9022)
- Tamim Niazi (ORCID: https://orcid.org/0000-0002-6283-8920)
- Éric Vigneault (ORCID: https://orcid.org/0000-0002-7201-9400)
- Ricardo Rendon (ORCID: https://orcid.org/0000-0002-4670-8384)
- Srikala S. Sridhar (ORCID: https://orcid.org/0000-0002-6994-1285)
- Frédéric Pouliot (ORCID: https://orcid.org/0000-0002-6651-1079)
- Fred Saad (ORCID: https://orcid.org/0000-0003-2986-5617)
- Bobby Shayegan (ORCID: https://orcid.org/0000-0001-9570-610X)
- Kim Chi
- Brita Danielson
Institutions
- Dalhousie University (CA)
- University of British Columbia (CA)
- University of Ottawa (CA)
- University of Alberta (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Université Laval (CA)
- McGill University (CA)
- Université de Montréal (CA)
- McMaster University (CA)
Publication Details
- Journal
- Canadian Urological Association Journal
- Published
- 2025-05-01
- DOI
- https://doi.org/10.5489/cuaj.9240
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Canadian Urological Oncology Group
- Seagen
- Astellas Pharma
- Ipsen
- Bavarian Nordic